VRL/SEC/EXCHANGE

18.11.2016

Dept of Corporate services

I

n*e

Utock Exchange, Mumbai

3:Li!;: j^'.=u

iuu;"uni-ol7 ro*"rs

Mumbai
: Submission

of

Slr/Madam,
ase find enclosed herewith
ers and tiability atong
with
taken on recorO by-tne

Itl"ii ]i,ti,],i:.'

?,iT:i ff

:?,?I."f
r.l
Tj:l;:
^f ni

Financial Res,.rtts (provisionat),

Staten
suartr:r
on
so:bs"i?ii
q.rs^f1-th.e
meetrng held on
"nc"o
09..11.2016.

; ij I H: : i:: 9,.""", jJi# :iai""lJ ?;",""#s

th

ro u s

h xBRL

acknowledge the receipt.

Krng you.

rs faithfully,

pany Secretary)

VE]IUS REMEDI
Corporate Omce :
51 52, Industrial Area, phase- I,
Regd. Omce :

TIMITED
{Hry.) 134I i3, India

Urit.I:
1r3. lndia
l-

Manimajra,

Urit-II:

WebsiLe I ws.w venusremedies.com

www r!ffcindia.com

email : inf@venusremedies.com
.r\r N^ r r4r?taHIoqopr anno?n<

uhit,v

r/ENUS PHARMA CmbH

AM Bahnhof

], D-59368. Werne. cermary

I72 2565566

FINANCIAL REFULTS (PROVISIONAL)

FOR

E OUARTER ENDED 3OTH SEPTEMBER, 2016

No
Net Sales/ Income

from operations

(a) Net Sales ( Net of Excase Dury

)
(b) Olher Operating Income

Total lncome tfom Operation ( Net

Expenses
(a) Consumptioo of raw materials
(b) (locrease)/ Decfease in slock in
trade
(c) Employee benefits expense
(d) Depreciation & amonisatton expense
(e) Other expenses

Total expense
Protit from operations before other
financo costs and exceptional items

EBIDTA ( 3+2(D)
Other Income

'178.94

Profit before finance costs and

items (3+4)
6

Finance Costs

Profit after finance costs but before

Exceptionatitems

94.55

81.39

E3

69

Profit frorh ordinary activities before tax

7+8)

1'l Pfotit from ordinary activities after

tax
12

Exceptionat items

13 Net

profit for the period ( 1't-12i)

55
11.84

87 37
16.05

152 69

1'1.41

1'r,84

16.05

11.41

11.84

16.05

Annualised

11.41

14 Paid up Equity Share Capital

15 Reserves excluding revaluation
16 E.P.S - Basic not annualised
for

10

114.
N, A,

the

2 74

175.94

'11.41

Tax Expenses

11
103.42

items ( 5-6)

'10

371.8

124

11,84
114.42

16.05
't'14.42

114.42

N. A,

N, A,

N, A.

'1.03

4.14

5.61

For

-Drsr

2.03
4.06

REI,]EDiES

Notes:

1.

The above financial

record at the Board

Its were reviewed by the ,Audit Committee and

on November 09, 2016.

Statutory auditors have

rried out the Limited Review for the said results.

The Company caters to

ly one segment i.e. "Pharmaceutical Formulations"

Previous quarter/pe

's figures have been

regroupedi rearranged

ken on

vYnerever

necessary.

For and on behalf of Board of Di

to rs
For VENUS REMEDTES Ll ITED
EDlES LII.'

Date: 09

11 2016

(Chairma n

Pawan Chau
e Managing Di

ry
r)
503

e Statement of Assets and Liabilities

Venus Remedies Limited

Half Year Ended

EQUITY AND

ES

Year Ended on

30/09/:2016i

31t03t2016

(Rs In N4illions)i

(Rs In Millions )

Shareholders' fu
(a) Share

114.42

(b) Reserves a

Sub-total

on

surplus

'funds

114 42,

4353 12

4329.87

4467 .54

4444 29

1814 32

Non-cu rrent lia

(a) Long-term
(b) Deferred
(c) Other

liabilities (net)

165.86

5 91

634

34 81

37 88

2020 91

2120 34

1163 64

1.'150.86

30.55

239.02

403 95

366 34

liabilities

(d) Long{erm

Sub-total

liabilities

91 0.26

'165 87

3 Current liabilities
(a) Short{erm
(b) Trade

(c) Other

liabilities

(d) Short-term
Su

b-total

TOTAL

Current

EQUITY

5.7 5

bilities

1775I

D LIABILITIES

_qg4ojq

ASSETS

Non-current assets
(a) Fixed
(b) Non-current
(c) Long-term

Sub-total

Non

an0 aovances

assets

5183.94

5138 92

287 36

287 36

331 . 16

328 98

580:1 46

57

Current assets
(a) Current

(b) Inventories

(c) Trade

(d) Cash and

(e) ShorHerm

Sub-total
TOTAL

55 26

Current

ASSETS

equivalents
and advances

385.7

376 93

579.13

538.85

29 59

30 44

495 46

eao
--: noi

"-

2489 88

2585 27

8292 34

8340 53

J. K. JAIN & ASSOCIATES

C H A R T E )? E

D ACCOUNTANTS

S.C,O. 1136-37, rSector22-8, CHANDIGARH- 160 022

0172-270 4536-37 Fax : 0772-270 4537

E- moil : jk jcaps @ redtf lmoil.com
REVIEWREPORT
The Board ofDirectors,

Venus Remedies Limited

5 l-52, Industrial Area,
Panchkula

We have reviewed tJte

Remedies Limited for
responsibility of the
Directors/Committee of
statements based on our

statement of un-audited Financial Results of Venus

half yearly/Quarter ended 30.09.2016. This statemenr is the
s Management and has beerL approved by the Board of
Directors. Our responsibility is to jissue a report on these financial

We conducted our review

accordalce with the Standard on Review Engagement (SRE) 2400,
'Engagements to Review
statements' issued by the Institute of Chartered Accountants
of India. This standard
that we plan and perform the review to obtain moderate
assurance as to whether the
ial statements are fiee of material misstatement. A review is
limited primarily to
of company personnel and anzrlytical procedures applied to
financial data and thus
less assurance than an audit. We have not performed aa audit
and accordingly, we do not
an audit opinion.
Based on our review

believe that the

accordance with applicable
policies has not disclosed

listing agreement including

material misstatement.

as above, nothing has come to our attention that causes us to

statement of un-audited Quarterly financial results prepared in
lounting standards and other recognized accounting practices and
information required to be disclosed in terms of clause 41 of the

marurer in which

it is tcr be disclosed, or that it

contains any

for J. K. Jain &

Date : 09.11.2016
Place : Chandigarh

M.No.083r40
FRN.004025N